Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections

International Journal of Immunopathology and Pharmacology

Volumn 18, Issue 3, 2005, Pages 457-473

  Marinova, S ^a   Nenkov, Plamen ^a   Markova, R ^a   Nikolaeva, S ^a   Kostadinova, R ^a   Mitov, I ^b   Vretenarska, M ^b  

^a NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Cell mediated immunity; Mucosal immunity; Oral immunization; Polybacterial immunomodulator; Proinflammatory cytokines; Urinary tract infections; Urostim

Indexed keywords

BACTERIUM ANTIBODY; BACTERIUM LYSATE; CYTOKINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MITOGENIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROSTIM;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; BLOOD SAMPLING; CELL ULTRASTRUCTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ELECTRON MICROSCOPY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; MUCOSAL IMMUNITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SALIVA; STATISTICAL SIGNIFICANCE; URINARY TRACT INFECTION;

EID: 27444441060     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200501800306     Document Type: Article

References (59)

1. th framework programme: pushing the envelope. Vaccine 21 (S):121.
2. Mestecky J. and P.N. Fultz. 1999. Mucosal immune system of the Human genital tract. J. Inf. Dis. 179 (S):470.
3. Koukalova D., V. Hajek and R. Kodusek. 1999. Development of a vaccine for treatment of urinary tract infections. Bratisl. Lek. Listy 100:92.
4. Belovezhdov N., Ch. Talakova, I. Chakurski, I. Angelova and G. Stefanov. 1985. Causative agents of uroinfections and their sensitivity to the most frequently used antibiotics and chemotherapeutic agents. Vutr. Boles.24:47.
5. Johanson I.M., K. Plos, B.L. Marklund and C. Svanborg. 1993. Pap. papG, and prsG DNA sequences in Escherihia coli from faecal flora and urinary tract. Pathol. 15:121.
6. Mitsumori K., A. Terai, S. Yamamoto, S. Ishitoya and O. Yoshida. 1999. Virulence Characteristics of Escherichia coli in Acute Bacterial Prostatitis. J. Inf. Dis. 180:1378.
7. Hagberg L., R. Hull and S. Hull. 1979. Contribution of adhesion to bacterial persistence in the mouse urinary tract. Infect. Immun.40:265.
8. Chick S., M.J. Harber, R. Mackenzie and A.W. Asscher. 1981. Modified method for studying bacterial adhesion to isolated uroepitelial cells and uromucoid. Infect. Immun. 34:256.
9. Kisielius P.V., W.R. Schwan, S.K. Amundsen, J.L. Duncan and A.J. Schaffer. 1986. In vivo expression and variation of Escherichia coli type 1 and P Pili in the urine of adults with acute urinary tract infections. Infect. Immun.57:1656.
10. Foxman B., L. Zhang, K. Palin, P. Tallman and C.F. Mars. 1995. Bacterial virulence characteristics of Escherichia coli isolates from first-time urinary tract infection. J. Inf. Dis. 171:1514.
11. Andren A., A.E. Stapleton, C. Fennell, H.A. Lockman, M. Xercavins, F. Fernandez and W.E. Stamm. 1997. Urovirulence determinants in Escherichia coli strains causing prostatitis. J. Inf. Dis. 176:464.
12. Jertborn M., C. Ahlen, J. Holmgren and A.M. Svennerholm. 1998. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. Vaccine. 16:2255.
13. Frey Ch., W. Obolensky and H. Wyss. 1986. Behandlung von rezidivierenden Harnwegsinektionen: Wirksamkeit eines oral verabreichten Immunobiotherapeutikums. Urol. Int. 41:444.
14. Van Pham T., B. Kreis, S. Corradin-Betz, J. Bauer and J. Mauel. 1990. Metabolitic and functional Stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies. J. Biol. Resp. Mod. 9:231.
15. Bessler W.G., P. Beck,. U. Konetznick, M. Loleit, E. Sedelmeier, P. Hoffman, M. Strecker and S. Stöclin. 1991. Biological activity of bacterial surface components. Immunogenicity and immunomodulatory properties of a bacterial extract from Escherichia coli. Arzneimittel-Forschung Drug Res. 41:274.
16. Penna F.J., L.A. Filho, A.C. Calcado, H.R. Junior and J.R. Nicoll. 2000. Up-to-date clinical and experimental basis for the use of probiotics. J. Pediatr. 76(S):S209.
17. Fioramonti J., V. Theodorou and L. Bueno. 2003. Probiotics: What are they? What are their effects on gut physiology? Best Pract. Res. Clin. Gastroenterol. 17:711.
18. Karimi O. and A.S. Pena. 2003. Probiotics: Isolated bacterial strain or mixtures of different strains? Two different approaches in the use of probiotics as therapeutics. Drugs Today 39:565.
19. Hadden J. W. 1993. Immunostimulants. Immunol. Today 14:275.
20. Stratev S., V. Grigorova and P. Panaiotov. 1993. Preoperative immunoprophylaxis in wound and urinary infections in urogenital patients with Urostim. Hirurgiia (Sofia) 46:9.
21. Nenkov P., I. Mitov, S. Marinova and R. Markova. 1995. Experimental investigations on the immunomodulating activity of polybacterial preparation for per oral immunotherapy and immunoprophylaxis of uroinfections. Int. J. Immunopharmacol. 17:489.
22. Markova R., S. Marinova, B. Petrunov, J. Cvetanov, P. Nenkov, A. Radinov, L. Tchorbadjiiska and D. Konstantinova. 1997. Stimulating effect of an oral polybacterial immunomodulator on the proliferative activity of guinea pig lymphocytes. Int. J. Immunopharmacol. 19:205.
23. Takahashi I., M. Marinaro, H. Kiyono, R.J. Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, J.D. Clements, K.L. Bost and J.R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Inf. Dis. 173:627.
24. Boersma Wim J.A. 1998. Modulation of mucosal immunity by probiotic microorganisms. Mucosal Immunol. 6:5.
25. Mitov I.G., A. Kropec, A. Benzing, H. Just, G. Garotta, C. Galanos and M. Freudenberg. 1997. Differential cytokine production in stimulated blood cultures from intensive care patients with bacterial infections. Infection 25:14.
26. Galanos C., O. Luderitz and O. Westphal. 1979. Preparation and properties of a standardized lipopolysaccharide from Salmonella abortus equi (Novo-Pyrexal). Zbl. Bakt. Hyg., I Abt. Orig. A 243:226.
27. Yaegashi Y., P. Nielsen, A. Sing, C. Galanos and M.A. Freudenberg. 1995. Interferon-β, as a co-factor in the interferon-α production induced by Gram-negative bacteria in mice. J. Exp. Med. 181:953.
28. Gallati H., I. Pracht, J. Schmidt, P. Haring and G. Garota. 1987. A simple, rapid and large capacity ELISA for biological active native and recombinant human IFN-γ. J. Biol. Regul. Homeost. Agents 1:109.
29. Freudenberg M.A. and C. Galanos. 1991. Tumour necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect. Immun. 59:2110.
30. Aarden L.A., E.R. DeGroot, O.L. Shaap and P.M. Lansdorp. 1987. Production of hybridoma growth factor by monocytes. Eur. J. Immunol. 17:1411.
31. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J. Immunol. Methods 65:55.
32. Marinova S., L. Tchorbadjiiska, B. Petrunov, J. Cvetanov, P. Nenkov, D. Konstantinova and R. MarkÓva. 2000. Immunostimulating and protective effects of an oral polybacterial immunomodulator "Dentavax" in a rabbit experimental model. Int. J. Immunopharmacol. 22:843.
33. Luber A.D., R.A. Jacobs, M. Jordan and B. J. Guglielmo. 1996. Relative Importance of oral versus in the Development of Vancomycin-Resistant Enterococci. J. Inf. Dis. 173:1292.
34. Hadden E.M., W.Y.M. Sosa, R.G. Coffey, A. Giner-Sorolla and J.W. Hadden. 1995. Methyl inosine monophosphate (MIMP) augments T-lymphocyte mitogen responses and reverses various immunosuppressants. Int. J. Immunopharmacol. 17:763.
35. Schlottfeldt J., L.R. Blazina, C.M.D. Wannmacher and M. Wajner. 1995. The effect of organic acids on phytohaemagglutinin-activated proliferation of human lymphocytes in vitro. Int. J. Immunopharmacol. 17:175.
36. Martinelli F., M. Corulli, F. Dima, F. Fallacara, et al. 1996. Heat-killed Bacillus subtilis inhibits T-cell proliferative response to mitogens and recall antigens. Int. J. Immunopharmacol. 18:701.
37. Rayward J., V.G. Villarrubia, C. Guillen, A. Prieto, M. Rodriguez-Zapata, G. Sada and M. Alvarez-Mon. 1997. An extract of the fern Polypodium leucotomos inhibits human peripheral blood mononuclear cells proliferation in vitro. Int. J. Immunopharmacol. 19:9.
38. Sang B.H., M.K. Hwan, H.K. Young, et al. 1998. T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. Int. J. Immunopharmacol. 20:1.
39. Huber M., K. Krauter, G. Winkelmann, H. W. Bauer, V.W. Rahlfs, P.A. Lauener, G.S.S. Bleßmann and W.G. Bessler. 2000. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int. J. Immunopharmacol. 22:1103.
40. Hoffmann P., K. Mittenbuhler, W.G. Bessler, L. Heinevetter, K.H. Wiesmuller, G. Jung, W. Baier, M. Huber, A.R. Lorenz and U.V.D. Esche. 1997. Bacterial cell wall components as immunomodulators-I. Lipopeptides as adjuvants for parenteral and oral immunization. Int. J. Immunopharmacol. 19:547.
41. Blanchard D.K., H. Friedman, T.W. Klein and J.Y. Dieu. 1992. Induction of interferon-gamma and tumor necrosis factor by Legionella pneumophila: augmentation of human neutrophil bactericidal activity. J. Leuk. Biol. 45:538.
42. Grau G.E., S.K. Parida, P. Pointaire, P.F. Barnes and R. Modlin. 1992. TNF and mycobacteria. In: Tumor Necrosis Factor: The Molecules and their Emerging Role in Medicine. B.Beutler, ed. Rawen Press Ltd. New York, p. 329.
43. Nakane A. 1992. TNF in listeriosis. In Tumor Necrosis Factor: The Molecules and Their emerging Role in Medicine B. Beuther ed. Raven Press New York, p. 285.
44. Kamijo R., L. Junping, D. Shapiro, E.A. Havell, S. Huang, M. Aguet, M. Bosland and J. Vilcek. 1993. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J. Exp. Med. 178:1435.
45. Rothe J., W. Lesslauer, H. Loetscher, Y. Lang, P. Koebel, F. Kuntgen, A. Althage, R. Zinkernagel, M. Steinmetz and H. Bluethmann. 1993. Mice lack in tumor necrosis factor receptor 1 is resistant to TNF mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798.
46. Sparwasser T., T. Miethke, G. Lipford, K. Borschert, Hacker H., K. Heeg and H. Wagner. 1997. Bacterial DNA causes septic shock. Nature 386:336.
47. Ferrante A., R.E.M. Staugas, B. Rowan-Kelli, S. Bresatz, L.M. Kumaratilake, C.M. Rzepczyk and G.R. Adolf. 1990. Production of tumor necrosis factor alpha and beta by human mononuclear leucocytes stimulated with mitogens, bacteria and malaria parasites. Infect. Immun. 58:3996.
48. Bosch J.A., H.S. Brand, T.J. Ligtenberg, B. Bermond, J. Hoogstraten and A.V. Nieuw Amerongen. 1996. Psychological stress as a determinant of protein levels and salivary-induced aggregation of Streptococcus gordonii in human whole saliva. Psychosom. Med. 58:374.
49. Drummond P.D. and B. Hewson-Bower. 1997. Increased psychosocial stress and decreased mucosal immunity in children with recurrent upper respiratory tract infections. J. Psychosom. Res. 43:271.
50. Ng V., D. Koh, G. Chan, H.Y. Ong, S.E. Chia and C.N. Ong. 1999. Are salivary immunoglobulin A and lysozyme biomarkers of stress among nurses? J. Occup. Environ. Med., 41:920.
51. Ng V., D. Koh, B. Mok, L.P. Lim, Y. Yang and S.E. Chia. 2004. Stressful life events of dental students and salivary immunoglobulin A. Int. J. Immunopathol. Pharmacol. 17(S):49.
52. Otsuki T., H. Sakaguchi, T. Hatayama, A. Takata, F. Hyodoh, S. Tsuujita, A. Ueki and K. Morimoto. 2004. Secretory IgA in saliva and academic stress. Int. J. Immunopathol. Pharmacol. 17(S):45.
53. Brandtzaeg P., E.S. Baekkevold, I.N. Farstad, F.L. Jahnsen, F.E. Johansen, E.M. Nilsen and T. Yamanaka. 1999. Regional specialization in the mucosal immune system; what happens in the microcompartments? Immunol. Today 20:141.
54. Brandtzaeg P. 2003. Mucosal immunity in infectious disease and allergy. International Congress Series 1257:11.
55. Bienenstock J. and A.D. Befus. 1980. Mucosal Immunology. Immunol. 4:249.
56. Brandtzaeg P. and B. Hanenberg. 1997. Role of nasal associated lymphoid tissue in the humoral mucosal immune system. Mucosal Immunology Update 5:4.
57. Perry M. and A. White. 1998. Immunology of the tonsils. Immunol Today 19:414.
58. Kiroytcheva M., B. Kiperova, F. Martinova, M. Baleva and I. Gruev. 1997. Immunotherapy of the recurrent urinary tract infections with the bacterial preparation Urostim. Sovremenna Medicina, XLVIII 5:13.
59. Nenkov P. 2000. Genes and Proteins Underlying Microbial Urinary Tract Virulence. In Overview on the Clinical Studies with Urostim Immunostimulator against Urogenital Infections. Emody et al., ed. Kluwer Academic Plenum Publisher, p. 325.